Optimer Pharmaceuticals says Dificid sales totaled nearly $12.2 million in the fourth quarter. Optimer could benefit from a proposed law that would lower development costs and speed up the regulatory process for new superbug-fighting antibiotics.

Optimer Pharmaceuticals says Dificid sales totaled nearly $12.2 million in the fourth quarter. Optimer could benefit from a proposed law that would lower development costs and speed up the regulatory process for new superbug-fighting antibiotics.

Trius Therapeutics Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • NEW: San Diego 500 — influential business leaders you need to know
Yours for only $129